Sarepta治疗 SRPT 深 沪
已收盘 09-26 16:00:00 美东时间
18.36
+0.640
+3.61%
华盛通- 最 高18.39
- 今 开17.64
- 成交量 406.03万股
- 最 低 17.57
- 昨 收 17.72
- 总市值 17.94亿
- 52周最高 138.81
- 市盈率 静 7.85
- 换手率 4.16%
- 52周最低 10.415
- 委 比 53.71%
- 总股本 9771.34万
- 历史最高 181.83
- 量 比 0.66
- 振 幅 4.63%
- 历史最低 0.433
- 每 手 1
- 风险率 19.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
BMO Capital Upgrades Sarepta Therapeutics to Outperform, Maintains Price Target to $50
BMO Capital analyst Kostas Biliouris upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Market Perform to Outperform and maintains the price target from $50 to $50.
09-22 19:21
Deckers Outdoor's signature brands running out of steam -- Bernstein
Deckers Outdoor Corp (NYSE:DECK) is a tale of two products – Uggs and Hoka – sales of which seem to be running out of steam and will ultimately put pressure on the company’s margins. A phenomenon that...
09-19 00:56
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analysts
Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 43 analysts in the last...
09-15 22:02
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Leerink Partners Maintains Market Perform on Sarepta Therapeutics, Raises Price Target to $15
Leerink Partners analyst Joseph Schwartz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Market Perform and raises the price target from $12 to $15.
09-09 22:08
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
09-02 23:47
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has entered into a global partnership with Novartis (NYSE:NVS), for the development of ARO-SNCA, the company's siRNA therapy aimed at treating synucleinopathies...
09-02 21:13
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Vor Bio appoints Adi Osovsky, S.J.D., as General Counsel, bringing 17 years of legal expertise in biotechnology and pharmaceutical sectors. Osovsky previously served as Executive Vice President, Head of Legal & Corporate Secretary at iTeos Therapeutics, and held senior roles at Sarepta Therapeutics. Her experience includes governance, strategic transactions, and risk management. Osovsky holds degrees from Tel Aviv University and Harvard Law Schoo...
09-02 12:00
